Clinical Trials Browser

Phase 1 × Ovarian Neoplasms × selinexor × Clear all

NCT02269293 2021-04-23

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

Phase 1 Completed

Ovarian Neoplasms, Endometrial Neoplasms